Enhancing U.S. Manufacturing Capabilities
In a bold move, Complete Genomics, a leader in genomic sequencing, has significantly expanded its U.S. manufacturing and technology capabilities. This expansion marks a crucial step towards establishing a diversified and reliable supply chain for next generation sequencing (NGS) solutions, enabling the company to meet the growing demands of its customers.
Strategic Localization Efforts
After navigating a challenging geopolitical landscape and witnessing the implications of the failed BIOSECURE Act, Complete Genomics launched a localization strategy in 2024. This initiative led to the establishment of two state-of-the-art facilities in the United States, enabling the company to build its first domestic supply chain aimed at enhancing local manufacturing capabilities.
New Manufacturing Facilities and Technological Advancements
In May 2024, Complete Genomics inaugurated a cutting-edge manufacturing facility at its headquarters in San Jose. This 10,115 square-foot facility is designed to streamline production processes and ensure faster delivery times for North American customers. With the new manufacturing site fully operational, the company has introduced DNBSEQ-G99RS sequencers, known as "G99," optimized for targeted gene and small genome sequencing. These sequencers boast an impressive run time of just 12 hours, with preliminary reporting available within the first 2.5 hours of sequencing.
Achieving Quality Standards
To enhance quality assurance, Complete Genomics has implemented robust training programs leading to its first Nationally Recognized Testing Laboratory (NRTL) certification for the G99 produced in North America. This certification is a testament to the company’s commitment to quality and reliability in its products.
Future Roadmap and Product Expansion
Looking ahead, Complete Genomics plans to further enhance its reagent production capabilities for both the G99 and DNBSEQ-T7RS sequencing platforms. The company is also actively pursuing ISO 13485 certification, a regulatory quality standard for medical device manufacturing. Rob Tarbox, VP of Product and Marketing at Complete Genomics, emphasized that the company is committed to local manufacturing and aims to initiate T7 production in the region.
Expanding Customer Experience and Support
Alongside the new San Jose plant, Complete Genomics has also expanded its presence on the East Coast. They recently launched a Customer Experience Center (CEC) in Framingham, designed to facilitate hands-on demonstrations of their DNBSEQ workflows to both current and prospective customers. This center showcases the latest advancements in next-generation sequencing platforms, sample prep systems, and bioinformatics solutions.
Strengthening Collaborations and Innovations
Throughout 2024, Complete Genomics has established several strategic partnerships to diversify its offerings. Collaborations with leading technology companies like NVIDIA have allowed Complete Genomics to incorporate advanced AI solutions into its genomic sequencing analysis. Furthermore, partnerships with industry leaders such as Eurofins Clinical Enterprise and AdvancedDx Biological Laboratories have broadened accessibility to its sequencing services.
Continuous Product Innovation
The commitment to product innovation has been central to Complete Genomics' strategy in 2024. The company has expanded its multi-omics and spatial transcriptomics applications, showcasing them at major industry events. For instance, the recently launched Spatial Xcellerator Grant Program is set to promote advancements in spatial omics research.
Commitment to Advancements in Genomic Research
Dr. Radoje Drmanac, the Founder and Chief Scientific Officer of Complete Genomics, reflected on the past year’s achievements, noting it as a transformative time for the organization. He underscored the significance of the expansions in manufacturing, customer support, and partnerships aimed at continuous growth in the genomic field. The company remains focused on advancing high-throughput sequencing technologies to support innovative research and clinical applications, reinforcing its position as a leader in genomic sequencing.
About Complete Genomics
Complete Genomics is a pioneering life sciences company renowned for providing novel DNA sequencing solutions. Since its inception in 2005, the company has been at the forefront of developing high-throughput, cost-effective sequencing technologies, contributing to over 9,400 scientific publications worldwide. With a strong dedication to quality and innovation, it empowers researchers and clinical practitioners to push the boundaries of genomic science. For more information, visit Complete Genomics.
Frequently Asked Questions
What are the new developments in Complete Genomics' manufacturing?
Complete Genomics has inaugurated new manufacturing facilities in the U.S. to enhance its supply chain and improve delivery times for customers.
Who is the VP in charge of product and marketing at Complete Genomics?
Rob Tarbox is the current VP of Product and Marketing at Complete Genomics, overseeing the company’s growth strategies.
What certifications has Complete Genomics achieved?
The company has obtained its first Nationally Recognized Testing Laboratory (NRTL) certification for the production of its G99 sequencers in North America.
What products does Complete Genomics focus on?
Complete Genomics specializes in next-generation sequencing technologies, including the DNBSEQ-G99 and DNBSEQ-T7RS platforms.
How does Complete Genomics support innovation in genomic research?
Complete Genomics fosters innovation through partnerships with technology leaders, product expansions, and initiatives like the Spatial Xcellerator Grant Program.
